{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:51:51Z","timestamp":1783644711203,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11940-016-0423-4","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T04:32:51Z","timestamp":1469680371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome"],"prefix":"10.1007","volume":"18","author":[{"given":"Linn E.","family":"Katus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Frucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"423_CR1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternback","year":"1991","unstructured":"Sternback H. The serotonin syndrome. Am J Psychiatry. 1991;148:705\u201313.","journal-title":"Am J Psychiatry"},{"key":"423_CR2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112\u201320. A comprehensive review of serotonin syndrome.","journal-title":"N Engl J Med"},{"issue":"2","key":"423_CR3","first-page":"155","volume":"24","author":"PJ Perry","year":"2012","unstructured":"Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155\u201362.","journal-title":"Ann Clin Psychiatry"},{"key":"423_CR4","doi-asserted-by":"crossref","unstructured":"Dosi R et al. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014.","DOI":"10.1136\/bcr-2014-204154"},{"key":"423_CR5","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1097\/CCM.0b013e31825ae0f8","volume":"40","author":"OJ Bienvenu","year":"2012","unstructured":"Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. Crit Care Med. 2012;40:2662\u201370. A concise review of syndrome features and specific treatment recommendations.","journal-title":"Crit Care Med"},{"key":"423_CR6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-12-214","volume":"12","author":"J Langan","year":"2012","unstructured":"Langan J et al. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome: literature review and case series report. BMC Psychiatry. 2012;12:214.","journal-title":"BMC Psychiatry"},{"key":"423_CR7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12028-008-9125-4","volume":"10","author":"EJ Newman","year":"2009","unstructured":"Newman EJ, Grosset DG, Kennedy PGE. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136\u201340.","journal-title":"Neurocrit Care"},{"key":"423_CR8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13311-013-0240-3","volume":"11","author":"S Frucht","year":"2014","unstructured":"Frucht S. Treatment of movement disorder emergencies. Neurotherapeutics. 2014;11:208\u201312.","journal-title":"Neurotherapeutics"},{"key":"423_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2146\/ajhp110543","volume":"70","author":"ME Musselman","year":"2013","unstructured":"Musselman ME, Suprat S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health-Syst Pharm. 2013;70:34\u201342.","journal-title":"Am J Health-Syst Pharm"},{"key":"423_CR10","unstructured":"Product information Dantrium (Dantrolene sodium). Pfizer Australia Pty Ltd. 2010."},{"key":"423_CR11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hrtlng.2013.11.009","volume":"43","author":"O Davies","year":"2014","unstructured":"Davies O et al. Full recovery after severe serotonin syndrome, severe rhabomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Heart Lung. 2014;43:117\u20139.","journal-title":"Heart Lung"},{"key":"423_CR12","unstructured":"Product information periactin (cyproheptadine hydrochloride). Aspen Pharmacare Australia Pty Ltd. 2011."},{"key":"423_CR13","unstructured":"Product monograph teva-chlorpromazine. Teva Canada Limited. 2012."},{"key":"423_CR14","unstructured":"Prescribing information for Zyprexa (Olanzepine): Eli Lilly and Company. 2014."},{"key":"423_CR15","unstructured":"Prescribing information for Parlodel (Bromocriptine mesylate). Validus Pharmaceuticals LLC. 2014."},{"issue":"2","key":"423_CR16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5498\/wjp.v5.i2.182","volume":"5","author":"F Luchini","year":"2015","unstructured":"Luchini F et al. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015;5(2):182\u201392.","journal-title":"World J Psychiatry"},{"key":"423_CR17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/WNF.0000000000000076","volume":"38","author":"YC Cheng","year":"2015","unstructured":"Cheng YC et al. Serotonin Syndrome after electroconvulsive therapy in a patient on trazodone, bupropion, and quetiapine: a case report. Clin Neuropharm. 2015;38:112\u20133.","journal-title":"Clin Neuropharm"},{"key":"423_CR18","doi-asserted-by":"crossref","unstructured":"Klysner R et al. Transient serotonin toxicity evoked by combination of electroconvulsive therapy and fluoxetine. Case Rep Psychiatry. 2014: 162502.","DOI":"10.1155\/2014\/162502"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0423-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0423-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0423-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:27:00Z","timestamp":1656894420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0423-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["423"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0423-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"article-number":"39"}}